An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy

• Published in: Internal Medicine Vol. 59; no. 3; pp. 395 - 399
• Main Authors: Yoshizawa, Tsuyoshi, Yamaguchi, Kenya, Kawata, Nozomu, Ryuzaki, Hitomi, Ogawa, Masahiro, Obinata, Daisuke, Mochida, Junichi, Takahashi, Satoru
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01-02-2020; Japan Science and Technology Agency
• Subjects: abiraterone; Case Report; Castration; Chemotherapy; Clinical aspects; durable complete response; ERG gene; Fluorescence in situ hybridization; Internal medicine; Metastases; Metastasis; metastatic castration-resistant prostate cancer; Prostate cancer; ERG gene; fluorescence in situ hybridization; metastatic castration-resistant prostate cancer; abiraterone; durable complete response
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.3302-19

We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of two cases with mCRPC that simultaneously investigated the ERG gene status and clinical aspects, including image evaluations and pathology.